On page 67 in the Hematology 2012 American Society of Hematology Education Program, there were errors in Table 2. For the drug “Decitabine” in the “Reference” column, the reference “4” was misplaced in the second row. It should have been placed in the third row.

For the drug “Azacitidine” in the “Dose/schedule” column, there are five rows with errors. The third row, “75 mg/m2/d SC 5-2-2” should have read, “75 mg/m2/d SC/IV 5-2-2.” The fourth row, “75 mg/m2/d SC × 5 d,” should have read, “75 mg/m2/d SC/IV × 5 d.” The fifth row, “75 mg/m2/d SC 5-2-5,” should have read, “75 mg/m2/d SC/IV × 7 d.” The sixth row, “50 mg/m2/d SC 5-2-2” should have read, “75 mg/m2/d SC 5-2-2.” The seventh row, “50 mg/m2/d SC × 5 d,” should have read, “75 mg/m2/d SC × 5 d.”

The corrected Table 2 is shown. The errors have been corrected in the online version, which now differs from the print version.

Table 2.

Clinical studies with hypomethylating agents in IPSS lower-risk MDS patients

Clinical studies with hypomethylating agents in IPSS lower-risk MDS patients
Clinical studies with hypomethylating agents in IPSS lower-risk MDS patients

N indicates number of patients; ORR, overall response rate; TID, 3 times/d; and SC, subcutaneous.